Seller record · telehealth service · directmeds.com
Direct Meds
A telehealth service selling compounded semaglutide and tirzepatide. An FDA warning letter names the operating entity, and the seller continues to operate.
Passes 6 of 8 criteria. 1 not verified, counting neither way. Recorded against Standard v1.1, August 2026.
Dispositions at a glance
| Code | Criterion | Disposition |
|---|---|---|
| S1 | Prescriber requirement | PASS |
| S2 | Prescription gating | PASS |
| S3 | Pharmacy identification | FAIL |
| S4 | Compounding disclosure | PASS |
| S5 | Analytical documentation | NOT VERIFIED |
| S6 | Business address | PASS |
| S7 | Price disclosure | PASS |
| S8 | Enforcement status | PASS |
Evidence, criterion by criterion
What was read, where, and on what date, for each disposition in the table above.
Products shown on the seller's own pages at the recorded date: compounded semaglutide (sublingual and injection), tirzepatide, NAD+, sermorelin, glutathione, BPC-157.
Visit Direct Meds›Partner link. The site earns a commission on care started through it. Funding.
Dispositions recorded against Standard v1.1, August 2026. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.